Freestone Capital Holdings’s VanEck Biotech ETF BBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,714
Closed -$278K 443
2022
Q1
$278K Buy
+1,714
New +$278K 0.01% 482

Other funds holding BBH

Freestone Capital Holdings's BBH Position: Q2 2022 in Review

Freestone Capital Holdings sold out of VanEck Biotech ETF (BBH) in Q2 2022, closing a stake of 1,714 shares — an estimated $278K sold.

Freestone Capital Holdings first reported a position in BBH in Q1 2022 and held it in 1 quarter. The position peaked at $278K in Q1 2022. 108 funds tracked by Wall St. Rank hold BBH as of Q2 2022.

  • Freestone Capital Holdings reported no remaining VanEck Biotech ETF position as of Q2 2022 after selling out during the quarter.
  • Freestone Capital Holdings sold 1,714 VanEck Biotech ETF shares in Q2 2022, an estimated $278K.
  • Freestone Capital Holdings first reported a position in VanEck Biotech ETF in Q1 2022 and held it in 1 quarter.
  • Freestone Capital Holdings's VanEck Biotech ETF position peaked at $278K in Q1 2022.
  • 108 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q2 2022.

Based on Freestone Capital Holdings's 13F filing for Q2 2022, filed 9 Aug 2022.